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Abstract
Background:  The combination therapies recommended by the World Health Organization for
treatment of brucellosis are doxycycline plus rifampicin or doxycycline plus streptomycin. Although highly
successful results have been obtained with these two regimens, relapse rates as high as 14.4%. The most
effective and the least toxic chemotherapy for human brucellosis is still undetermined. The aim of the
present study was to investigate the efficacy, adverse effects and cost of ofloxacin plus rifampicin therapy,
and doxycycline plus rifampicin therapy and evaluate in the treatment of brucellosis.
Methods: The open trial has been carried out prospectively by the two medical centers from December
1999 to December 2001 in Duzce region Turkey. The diagnosis was based on the presence of signs and
symptoms compatible with brucellosis including a positive agglutination titre (≥1/160) and/or a positive
culture. Doxycycline and rifampicin group consisted of 14 patients who were given doxycycline 200 mg/
day plus rifampicin 600 mg/day during 45 days and this group Ofloxacin plus rifampicin group was consisted
of 15 patients who were given ofloxacin 400 mg/day plus rifampicin 600 mg/day during 30 days.
Results:  Regarding clinical and/or demographic characteristics no significant difference was found
between two groups of patients that underwent two different therapeutic regimens. At the end of the
therapy, two relapses were seen in both groups (p = 0.695). Although duration of therapy was two weeks
shorter in group treated with rifampicin plus ofloxacin, the cure rate was similar in both groups of
examinees. Fever dropped more rapidly in the group that treated with rifampicin plus ofloxacin, 74 ± 30
(ranges 48–216) vs. 106 ± 26 (ranges 48–262) hours (p = 0.016).
Conclusions:  Ofloxacin plus rifampicin therapy has advantages of shorter treatment duration and
provided shorter course of fever with treatment than in doxycycline plus rifampicin therapy. However,
cost of ofloxacin plus rifampicin treatment is higher than doxycycline plus rifampicin treatment. Because
of the similar effects, adverse effects and relapses rates between two regimens, we still advice doxycycline
plus rifampicin for the treatment of brucellosis for countries, which have limited resources.
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Background
Brucellosis is a systemic infection caused by facultative
intracellular bacteria of the genus Brucella that manifests
the most commonly as fever of unknown origin. Brucello-
sis remains a major zoonosis worldwide and it is endemic
in certain parts of Turkey. Currently, the most commonly
used antibiotics in the treatment of brucellosis are tetracy-
cline, trimethoprim-sulfamethoxazole, aminoglycosides,
rifampicin, quinolones and chloramphenicol [1,2]. These
antibiotics are used alone or in combination. However,
due to frequent relapses observed with monotherapy,
combined therapy is recommended [3]. Currently, the
combination therapies recommended by the World
Health Organization for treatment of brucellosis are dox-
ycycline plus rifampicin or doxycycline plus streptomycin.
Although highly successful results have been obtained
with these two regimens, relapse rates as high as 14.4%
[4]. The most effective and the least toxic chemotherapy
for human brucellosis is still undetermined [3].
The present study was undertaken to evaluate the efficacy,
safety, and cost effectiveness of doxycycline plus
rifampicin regimen for 45 days compared to ofloxacin




This study was carried out in the Social Security Duzce
Hospital and Abant Izzet Baysal University Duzce Medical
School in Turkey. After obtaining informed consent, a
detailed medical history was taken from each patient and
complete physical examination was performed. Patients
suspected to have brucella infection on the basis of clini-
cal (fever, limb and back pains, sweating, fatigue,
hepatomegaly, splenomegaly, arthritis, sacroileitis,
spondylitis, orchitis and headache) and laboratory find-
ings were hospitalized. The diagnosis was based on the
presence of signs and symptoms compatible with brucel-
losis including a positive agglutination titre (≥1/160)
and/or a positive culture [3]. All sera obtained from the
patients were examined by serial dilution (from 1:10 to
1:1280) using bacterial antigen. The antigen was obtained
from the Ministry of Agriculture (Veterinary Research
Institute, Pendik, Istanbul).
Observation
Patients were hospitalized for at least 10 days at the begin-
ning of treatment in order to monitor clinical response
and potential side effects. The patients were assessed and
laboratory tests were also performed during the therapy
period in the 2nd, 4th, and 6th week of therapy. At the
end of therapy, laboratory tests were reassessed at months
1, 2, 3 and as well as whenever clinical symptoms
reappeared.
Biphasic Castenade medium was used for blood and bone
marrow cultures. Complete blood count (CBC), and rou-
tine biochemical tests, erythrocyte sedimentation rate
(ESR), urine for urinalysis, and stool, urine and at least
three blood cultures were determined at baseline, and all
scheduled follow -up visits. Bone marrow aspirate cultures
obtained three patients. Blood cultures, standard tube
agglutination test, and clinical evaluations were done
monthly during the first 3 months post therapy. Addi-
tional studies were performed as needed.
Sample size and randomization
Sample size was determined according to the patients
who were admitted to the study with brucella infection in
the study period. Patients who met the criteria for entry
were randomly assigned to receive in a 1:1 ratio in doxy-
cycline plus rifampicin or ofloxacin plus rifampicin
group. Doxycycline plus rifampicin group had 14 patients
who received doxycycline 100 mg two times daily and
rifampicin 600 mg once daily for 45 days. Ofloxacin plus
rifampicin group had 15 patients who received ofloxacin
400 mg once daily and rifampicin 600 mg once daily for
30 days.
Exclusion
Exclusion criteria were history of seizure, pregnancy and
age under 15 years. Between December 1999 and Decem-
ber 2001, 34 (24 male and 10 female) patients were
recruited. 29 patients (24 male and 5 female) completed
this study in the follow-up period. These criteria were car-
ried out both groups. Four patients were excluded from
doxycycline plus rifampicin group. Because they felt well,
they didn't complete the therapy. One patient was
excluded in the ofloxacin plus rifampicin group because
he didn't want to use drugs two weeks after starting to the
treatment. As a result five patients were excluded from the
study (Fig. 1).
Ethics
The study protocol was approved by the local ethics com-
mittee. All patients were informed about study and agreed
to contribute in the study by signing informed consent.
Assessment of efficacy
The primary end point was existence of clinical relapse.
Relapse was defined as the reappearance of symptoms and
sign of the disease accompanied by increasing titers of the
serological tests and/or a positive culture during the fol-
low-up period after treatment was stopped [1,15].
The secondary end point was accepted as the duration of
fever after starting treatment. Fever of patients who were
started to treatment was measured by axillary route and
recorded every hour until it decreased to 37°C.BMC Infectious Diseases 2004, 4:18 http://www.biomedcentral.com/1471-2334/4/18
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Analysis
Duration of fever after starting treatment was compared
between the two groups using non-parametric test (Mann-
Whitney test). The data of the other parameters were ana-
lyzed using Fisher's exact test. We used Epi-info 6.0 (Cent-
ers for Disease Control, Atlanta) to perform the analysis
and considered p < 0.05 as significant.
Results
Comparisons of the clinical and demographic findings in
the doxycycline plus rifampicin group and ofloxacin plus
rifampicin are presented in Table 1. Doxycycline plus
rifampicin group and ofloxacin plus rifampicin group
were followed up after treatment 149 ± 74 days, 156 ± 15
days (mean ± SD) respectively.
In two patients in doxycycline plus rifampicin group and
two patients in ofloxacin plus rifampicin group clinical
relapse during the follow-up period was observed. The
organism could not be isolated in these patients. No sta-
tistically significant differences in the relapse rates
between the two therapy groups were found
After starting treatment, fever disappeared within an aver-
age of 106 ± 26 (ranges 48–262) hours in doxycycline
plus rifampicin group and 74 ± 30 (ranges 48–216) hours
for ofloxacin plus rifampicin group (p = 0.016, CI 95%:
21.21–41.06).
Nausea and vomiting were registered in three patients in
doxycycline plus rifampicin group and in one patient in
ofloxacin plus rifampicin group. Diarrhea was seen in one
patient in doxycycline plus rifampicin group and two
patients in ofloxacin plus rifampicin group.
After the failure of the study regimens, these patients were
given doxycycline 100 mg two times daily for 6 weeks plus
streptomycin 1 g/day for 3 weeks.
Discussion
Human brucellosis has a serious medical impact world-
wide, and its eradication poses major difficulties [5]. In
Turkey, annually reporting cases of brucella are approxi-
mately 15.000 according to the data of the Ministry of
Health Turkey in 2001 year. However it is believed that
the real number of the cases is at least 50.000–100.000
Flow chart of the patients in the study Figure 1
Flow chart of the patients in the study.BMC Infectious Diseases 2004, 4:18 http://www.biomedcentral.com/1471-2334/4/18
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per year, when the unreported and subclinical cases are
taken into account. For this reason, brucellosis is an
important problem in our country [6].
Treatment of brucellosis must effectively control acute ill-
ness and prevent complications and relapse. The regimen
of choice and duration of antimicrobial therapy should be
based on the presence of focal disease and underlying
conditions that contraindicate certain specific antibiotics.
Selection of therapeutic regimen and duration of therapy
depend on clinical presentation of the disease, as well as
on underlying diseases and/or conditions that could be
contraindication for some antimicrobial agents. Tetracy-
clines are generally contraindicated for pregnant patients
and children under 8 years of age. Rifampicin 900 mg
once daily for 6 weeks is considered as a drug of choice for
treating brucellosis in pregnant women. The preferred reg-
imen in children under 8 years of age is rifampicin with
cotrimoxazole (trimethoprim-sulfamethoxazole) for 45
days. Appropriate antimicrobial therapy and duration of
the treatment of human brucellosis will reduce morbidity,
prevent complications, and diminish relapses [7].
In the present study, doxycycline plus rifampicin therapy
for 45 days was compared with ofloxacin plus rifampicin
therapy for 30 days in patients with brucellosis. Relapses
were seen in each group. There was no significant differ-
ence between the two regimens for relapse rates (p >
0.05). After starting treatment, fever disappeared within
an average of 106 ± 26 (ranges 48–262) hours in doxycy-
cline plus rifampicin group and 74 ± 30 (ranges 48–216)
hours for ofloxacin plus rifampicin group (p = 0.016). In
the present study, the average number of the days without
fever was higher in ofloxacin plus rifampicin group than
doxycycline plus rifampicin group.
Ciprofloxacin and ofloxacin are particularly active in vitro
against brucella infections [8]. However, only a limited
number of clinical studies have been conducted to test the
new quinolones against this organism [9,10,15]. In con-
trast to the results of in vitro studies, however, the findings
in clinical studies with floroquinolones have been contro-
versial. Monotherapy with these agents showed high
relapse rates [11,12]. Doganay et al. [11] in their clinical
study with 14 patients (one subacute and 13 acute infec-
tions) tested ciprofloxacin 500 mg thrice daily for 3–6
weeks as monotherapy for the treatment of brucellosis. All
patients, including those with complications, showed
clinical improvement at the end of ciprofloxacin therapy.
However three patients relapsed at week 4, week 5, and
month 4, after cessation of therapy, resulting in a relapse
rate of 21%. Lang et al. [12] reported high relapse rate of
66% among patients who received ciprofloxacin as mon-
otherapy. Al-Sibai et al. [13] administrated 750 mg cipro-
floxacin thrice daily for 6–8 weeks their 16 patients (9 of
whom had complication). Three patients relapsed 8–12
weeks after end of the therapy, and the resulting relapse
rate was reported as 25%. Patients treated with a single
agent such as tetracycline, rifampicin or ciprofloxacin
have a 10–40 percent chance of suffering a relapse there-
fore, many authorites suggest that combination therapy is
should be given, and quinolones monotherapy should
not be used [3,12].
Table 1: Clinical characteristics and comparison of the Ofloxacin & Rifampicin and Doxycycline & Rifampicin group
Clinical findings Doxycycline & Rifampicin group (n = 14) Ofloxacin & Rifampicin group (n = 15)
Age (years) (median-range) 29 (24–61) 35 (18–60)
Male/Female 11/3 13/2
Hepatomegaly (n) 7 9
Fever (n) 13 15
Arthralgia (n) 13 13
Headache (n) 10 11
Sweating (n) 12 10
Splenomegaly (n) 7 7
Diagnosis with culture (n) 4 3
Diagnosis with agglutination (n) 12 13
Adverse effects
- Diarrhea (n) 1 2
- Nausea and vomiting (n) 3 1
Complication (n) 2 Sacroileitis 1 Sacroileitis **
1 Orchitis
Relapse (n) 2 2 **
Duration of fever after starting treatment (mean ± SD) (hours) 106 ± 26 74 ± 30 *
*p < 0.05. ** p > 0.05BMC Infectious Diseases 2004, 4:18 http://www.biomedcentral.com/1471-2334/4/18
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In the study, two regimens were compared for the side
effects and costs. Nausea was seen in three of 14 patients
who were adminestered doxycycline plus rifampicin and
one of 15 patients who were administered ofloxacin plus
rifampicin. Diarrhea was seen in one of 14 patients who
were adminestered doxycycline plus rifampicin and in
two of 15 patients who were administered ofloxacin plus
rifampicin. These results suggested that there were similar
side effects with both regimens. Cost of ofloxacin plus
rifampicin treatment during 30 days is 45 $ whereas cost
of doxycycline plus rifampicin during 45 days is 25$. In
point of cost effectiveness, doxycycline plus rifampicin
treatment is approximately twice superior to ofloxacin
plus rifampicin. This is an important difference especially
in countries with limited resources.
In the present study, we administered ofloxacin plus
rifampicin to patients with brucellosis for 30 days, which
was approximately two weeks shorter course than the
standard doxycycline plus rifampicin regimen. No signifi-
cant difference in success rates was observed between the
two groups. The therapies that cause disappearance of the
symptoms in short time increase the compliance of the
patients [14]. Agalar et al. [15] compared doxycycline plus
rifampicin for 45 days versus ciprofloxacin plus
rifampicin for 4 weeks. In one-year follow-up they
reported relapses rates were 15% and 10% for doxycycline
plus rifampicin therapy and ciprofloxacin plus rifampicin
therapy, respectively. They reported that the ciprofloxacin
plus rifampicin combination was as effective as the doxy-
cycline plus rifampicin combination and patient compli-
ance was superior the ciprofloxacin plus rifampicin
combination than the doxycycline plus rifampicin combi-
nation. Similarly, in the present study, that the comple-
tion of treatment 15 days ago and early improvement of
fever in patients who administered ofloxacin plus rifamp-
isin therapy increased satisfaction of the patients such as
the adaptation of the therapy.
It is important to consider the limitations of this study. In
the present study, 14 cases were evaluated in doxycycline
plus rifampicin group and 15 in ofloxacin and rifampicin
group. In order to detect a minimum difference of 14%
between two groups of patients, the beta error would be
0.52. On the other hand, a true difference between regi-
mens (i.e., alpha = 0.05 and beta = 0.20) would require 26
patients to be allocated to each of the treatment groups.
Our study group was small and thus might lack power to
distinguish a true difference between the treated group
and the control group. We think that further studies, espe-
cially larger well-designed ones, are needed to therapy for
brucella infection.
Conclusion
On the basis of our results, we conclude that ofloxacin
plus rifampicin for the treatment of human brucellosis is
as effective as the standard doxycycline plus rifampicin
regimen. Although, ofloxacin plus rifampicin decreased
the duration of the therapy and provided shorter course of
fever, however these superiorities are not sufficient for
declaring this treatment as treatment of choice. Difference
in costs between two regimens in our country is signifi-
cant and approximately two fold higher for ofloxacin plus
rifampicin treatment. Because of similar effects, adverse
effects and relapses rates between two regimens, we still
advice doxycycline and rifampicin regimen in treatment
of brucellosis especially for countries with limited
resources.
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